Medicare Transaction Fraud Prevention Act

Who is affected and how:

• Medicare beneficiaries: Those who opt in could see quicker detection and potential suspension of questionable payments for certain DME and lab services; opt-in protects beneficiaries who do not want to participate, but participating beneficiaries may experience delays in claims processing while reviews occur and will receive electronic notices.

• Health care providers and suppliers (including DME suppliers and clinical laboratories): May face increased scrutiny of claims selected by the algorithm, more documentation requests, and potential payment suspensions pending human review. Providers will need to receive and respond to notifications and may incur administrative burden to address reviews and appeals.

• CMS and program integrity operations: Will pilot and operate the algorithm, manage notifications, run human review processes, and coordinate with industry. The agency will need technical capability to test, validate, and monitor algorithm performance and to implement safeguards.

• Algorithm developers and IT vendors: May be engaged for development, validation, and ongoing support of the predictive scoring tool; collaboration with industry is required by the pilot.

Overall effects:

• Potential reduction in improper payments or faster identification of high-risk claims if the algorithm performs well.
• Increased administrative workload for providers and CMS related to notifications, documentation, and human reviews.
• Privacy, transparency, and due-process concerns could arise if algorithmic decisions are not well-explained; the statute includes opt-in and human-review safeguards to reduce such risks.
• Because the pilot is time-limited and opt-in, impacts will be narrower than a mandatory, nationwide roll-out but will still test operational and legal issues around automated risk scoring in Medicare payment oversight.